Table 2.
ncRNA molecules with significant roles in doxorubicin-mediated cardiotoxicity
| ncRNA | Cell type | Species | Levels | Mechanism | Therapeutic Approach | Reference |
|---|---|---|---|---|---|---|
| miR-208a | Myocytes | Mouse | Upregulated | Targets Gata4 | Silencing | Tony et al. (53) |
| miR-532-3p | CM | Mouse in vivo; human, rat, mouse in vitro | Upregulated | Targets ARC | Silencing | Wang et al. (58) |
| miR-30e | CM | Rat | Downregulated | Targets β1AR, β2AR, Gia-2, and BNIP3L | Induction | Roca-Alonso et al. (41) |
| miR-320a | EC | Mouse in vivo; human in vitro | Upregulated | VEGF-A | Silencing | Yin et al. (66) |
| miR-34a | EC, CPC | Rat | Upregulated | Targets Bcl2 and Sirt1 | Silencing | De Angelis et al. (12) |
| miR-146a | CM | Mouse | Upregulated | Regulates ErbB4 | Silencing | Horie et al. (24) |
| Mhrt | CM | Rat | Downregulated | Regulates Nrf2 | Induction | Li et al. (27) |
| Chrf | CM | Mouse | Upregulated | Targets TGF-β/Smads; TGF-β/p38 | Silencing | Chen et al. (8) |
| H19; miR-675 | CM | Rat | Upregulated | Regulates miR-675; Ebp1 | Silencing | Zhang et al. (68) |
| Ttn105-111 | CM | Mouse | Upregulated | Regulated by Qki5 | Silencing | Gupta et al. (20) |
ncRNA, noncoding RNA; CM, cardiomyocytes; EC, endothelial cell; CPC, cardiac progenitor cells ARC, apoptosis repressor with caspase recruitment domain; β1AR, β2AR, β-adrenergic receptor 1 and 2; BNIP3L, BCL2 interacting protein 3 like; VEGF-A, vascular endothelial growth factor A; SIRT1, sitrtuin1; ErbB4, Erb-B2-receptor tyrosine kinase 4; Mhrt, myosin heavy chain associated RNA transcript; Nrf2, nuclear factor erythroid 2 related factor 2; Chrf, cardiac hypertrophy related factor; TGF-β, tumor growth factor-β; Ebp1, ErbB3-binding protein 1; Ttn, Titin; Qki, Quaking.